Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Cost Cuts, R&D Prioritization, Deals All On The Table
Executive Summary
Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.
You may also be interested in...
Blow For EU Tecfidera Rivals As Biogen Triumphs In Legal Battle
Developers of generic dimethyl fumarate have received a setback after a CJEU ruling in Biogen’s favor gave Tecfidera EU regulatory marketing protection until at least February 2024.
Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
How Biogen’s Aduhelm Bet Became A Commercial Bust
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.